

References

1. Mankoff DA. A definition of molecular imaging. *J Nucl Med.* 2007;48:18N, 21N.
2. Fowler JS, Ido T. Initial and subsequent approach for the synthesis of 18FDG. *Semin Nucl Med.* 2002;32:6-12.
3. Wahl RL, Cody RL, Hutchins GD, Mudgett EE. Primary and metastatic breast carcinoma: initial clinical evaluation with PET with the radiolabeled glucose analogue 2-[F-18]-fluoro-2-deoxy-D-glucose. *Radiology.* 1991;179:765-770.
4. Gold LS, Klein G, Carr L, Kessler L, Sullivan SD. The emergence of diagnostic imaging technologies in breast cancer: discovery, regulatory approval, reimbursement, and adoption in clinical guidelines. *Cancer Imaging.* 2012;12:13-24.
5. *National Comprehensive Cancer Network Guidelines Version 2.2016 Invasive Breast Cancer*; 2016.
6. Fowler AM. A molecular approach to breast imaging. *J Nucl Med.* 2014;55:177-180.
7. Lee Y-TN. Breast carcinoma: pattern of metastasis at autopsy. *Journal of Surgical Oncology.* 1983;23:175-180.
8. Bastawrous S, Bhargava P, Behnia F, Djang DS, Haseley DR. Newer PET application with an old tracer: role of 18F-NaF skeletal PET/CT in oncologic practice. *Radiographics.* 2014;34:1295-1316.
9. Petren-Mallmin M, Andreasson I, Ljunggren O, et al. Skeletal metastases from breast cancer: uptake of 18F-fluoride measured with positron emission tomography in correlation with CT. *Skeletal Radiol.* 1998;27:72-76.
10. Hillner BE, Siegel BA, Hanna L, et al. Impact of (18)F-Fluoride PET on intended management of patients with cancers other than prostate cancer: results from the National Oncologic PET Registry. *J Nucl Med.* 2014;55:1054-1061.
11. Doot RK, Muzi M, Peterson LM, et al. Kinetic analysis of 18F-fluoride PET images of breast cancer bone metastases. *J Nucl Med.* 2010;51:521-527.

12. Oka S, Okudaira H, Yoshida Y, Schuster DM, Goodman MM, Shirakami Y. Transport mechanisms of trans-1-amino-3-fluoro[1-(14)C]cyclobutanecarboxylic acid in prostate cancer cells. *Nucl Med Biol.* 2012;39:109-119.
13. Tade FI, Cohen MA, Styblo TM, et al. Anti-3-18F-FACBC (18F-Fluciclovine) PET/CT of Breast Cancer: An Exploratory Study. *J Nucl Med.* 2016;57:1357-1363.
14. Ulaner GA, Goldman DA, Gonen M, et al. Initial results of a prospective clinical trial of 18F-fluciclovine PET/CT in newly diagnosed invasive ductal and invasive lobular breast cancers. *J Nucl Med.* 2016;57:1350-1356.
15. Ulaner GA, Goldman D, Corben A, et al. A prospective clinical trial of 18F-Fluciclovine PET/CT neoadjuvant therapy response in invasive ductal and invasive lobular breast cancers. *J Nucl Med.* 2016.
16. McConathy J. 18F-Fluciclovine (FACBC) and its potential use for breast cancer imaging. *J Nucl Med.* 2016;57:1329-1330.
17. Kole AC, Nieweg OE, Pruijm J, et al. Standardized uptake value and quantification of metabolism for breast cancer imaging with FDG and L-[1-11C]tyrosine PET. *J Nucl Med.* 1997;38:692-696.
18. Okudaira H, Shikano N, Nishii R, et al. Putative transport mechanism and intracellular fate of trans-1-amino-3-18F-fluorocyclobutanecarboxylic acid in human prostate cancer. *J Nucl Med.* 2011;52:822-829.
19. Hendrick RE, Tredennick T. Benefit to radiation risk of breast-specific gamma imaging compared with mammography in screening asymptomatic women with dense breasts. *Radiology.* 2016:151581.
20. Mainiero MB, Lourenco A, Mahoney MC, et al. ACR appropriateness criteria breast cancer screening. *J Am Coll Radiol.* 2013;10:11-14.
21. Hendrick RE. Radiation doses and cancer risks from breast imaging studies. *Radiology.* 2010;257:246-253.
22. Rhodes DJ, Hruska CB, Connors AL, et al. Journal club: molecular breast imaging at reduced radiation dose for supplemental screening in mammographically dense breasts. *AJR Am J Roentgenol.* 2015;204:241-251.

23. Brem RF, Ruda RC, Yang JL, Coffey CM, Rapelyea JA. Breast-specific gamma-imaging for the detection of mammographically occult breast cancer in women at increased risk. *J Nucl Med.* 2016;57:678-684.
24. van Es SC, Venema CM, Glaudemans AW, et al. Translation of new molecular imaging approaches to the clinical setting: bridging the gap to implementation. *J Nucl Med.* 2016;57 Suppl 1:96s-104s.
25. Schwarz SW, Oyama R. The role of exploratory investigational new drugs for translating radiopharmaceuticals into first-in-human studies. *J Nucl Med.* 2015;56:497-500.
26. Mankoff DA, Shields AF, Krohn KA. PET imaging of cellular proliferation. *Radiol Clin North Am.* 2005;43:153-167.
27. Kenny LM, Vigushin DM, Al-Nahhas A, et al. Quantification of cellular proliferation in tumor and normal tissues of patients with breast cancer by [18F]fluorothymidine-positron emission tomography imaging: evaluation of analytical methods. *Cancer Res.* 2005;65:10104-10112.
28. Smyczek-Gargya B, Fersis N, Dittmann H, et al. PET with [18F]fluorothymidine for imaging of primary breast cancer: a pilot study. *Eur J Nucl Med Mol Imaging.* 2004;31:720-724.
29. Chalkidou A, Landau DB, Odell EW, Cornelius VR, O'Doherty MJ, Marsden PK. Correlation between Ki-67 immunohistochemistry and 18F-fluorothymidine uptake in patients with cancer: A systematic review and meta-analysis. *Eur J Cancer.* 2012;48:3499-3513.
30. Kostakoglu L, Duan F, Idowu MO, et al. A phase II study of 3'-deoxy-3'-18F-fluorothymidine PET in the assessment of early response of breast cancer to neoadjuvant chemotherapy: results from ACRIN 6688. *J Nucl Med.* 2015;56:1681-1689.
31. Chae SY, Kim SB, Ahn SH, et al. A randomized feasibility study of 18F-fluoroestradiol positron emission tomography to predict pathological response to neoadjuvant systemic therapy in estrogen receptor-rich postmenopausal breast cancer. *J Nucl Med.* 2016.
32. van Kruchten M, de Vries EG, Brown M, et al. PET imaging of oestrogen receptors in patients with breast cancer. *Lancet Oncol.* 2013;14:e465-475.

- 33.** Mintun MA, Welch MJ, Siegel BA, et al. Breast cancer: PET imaging of estrogen receptors. *Radiology*. 1988;169:45-48.
- 34.** Peterson LM, Mankoff DA, Lawton T, et al. Quantitative imaging of estrogen receptor expression in breast cancer with PET and 18F-fluoroestradiol. *J Nucl Med*. 2008;49:367-374.
- 35.** Evangelista L, Dieci MV, Guarneri V, Conte PF. 18F-Fluoroestradiol positron emission tomography in breast cancer patients: systematic review of the literature and meta-analysis. *Curr Radiopharm*. 2016.
- 36.** McGuire AH, Dehdashti F, Siegel BA, et al. Positron tomographic assessment of 16 alpha-[18F] fluoro-17 beta-estradiol uptake in metastatic breast carcinoma. *J Nucl Med*. 1991;32:1526-1531.
- 37.** Dehdashti F, Mortimer JE, Siegel BA, et al. Positron tomographic assessment of estrogen receptors in breast cancer: comparison with FDG-PET and in vitro receptor assays. *J Nucl Med*. 1995;36:1766-1774.
- 38.** Dehdashti F, Flanagan FL, Mortimer JE, Katzenellenbogen JA, Welch MJ, Siegel BA. Positron emission tomographic assessment of "metabolic flare" to predict response of metastatic breast cancer to antiestrogen therapy. *Eur J Nucl Med*. 1999;26:51-56.
- 39.** Mortimer JE, Dehdashti F, Siegel BA, Katzenellenbogen JA, Fracasso P, Welch MJ. Positron emission tomography with 2-[18F]Fluoro-2-deoxy-D-glucose and 16alpha-[18F]fluoro-17beta-estradiol in breast cancer: correlation with estrogen receptor status and response to systemic therapy. *Clin Cancer Res*. 1996;2:933-939.
- 40.** van Kruchten M, Glaudemans AW, de Vries EF, et al. PET imaging of estrogen receptors as a diagnostic tool for breast cancer patients presenting with a clinical dilemma. *J Nucl Med*. 2012;53:182-190.
- 41.** Gemignani ML, Patil S, Seshan VE, et al. Feasibility and predictability of perioperative PET and estrogen receptor ligand in patients with invasive breast cancer. *J Nucl Med*. 2013;54:1697-1702.
- 42.** Peterson LM, Kurland BF, Schubert EK, et al. A phase 2 study of 16alpha-[18F]-fluoro-17beta-estradiol positron emission tomography (FES-PET) as a marker of hormone sensitivity in metastatic breast cancer (MBC). *Mol Imaging Biol*. 2014;16:431-440.

43. Yang Z, Sun Y, Xue J, et al. Can positron emission tomography/computed tomography with the dual tracers fluorine-18 fluoroestradiol and fluorodeoxyglucose predict neoadjuvant chemotherapy response of breast cancer?--A pilot study. *PLoS One*. 2013;8:e78192.
44. Groheux D, Majdoub M, Tixier F, et al. Do clinical, histological or immunohistochemical primary tumour characteristics translate into different (18)F-FDG PET/CT volumetric and heterogeneity features in stage II/III breast cancer? *Eur J Nucl Med Mol Imaging*. 2015;42:1682-1691.
45. Osborne CK, Schiff R. Mechanisms of endocrine resistance in breast cancer. *Annu Rev Med*. 2011;62:233-247.
46. Sundararajan L, Linden HM, Link JM, Krohn KA, Mankoff DA. 18F-Fluoroestradiol. *Semin Nucl Med*. 2007;37:470-476.
47. Nordenskjold A, Fohlin H, Fornander T, Lofdahl B, Skoog L, Stal O. Progesterone receptor positivity is a predictor of long-term benefit from adjuvant tamoxifen treatment of estrogen receptor positive breast cancer. *Breast Cancer Res Treat*. 2016;160:313-322.
48. Howell A, Harland RN, Barnes DM, et al. Endocrine therapy for advanced carcinoma of the breast: relationship between the effect of tamoxifen upon concentrations of progesterone receptor and subsequent response to treatment. *Cancer Res*. 1987;47:300-304.
49. Dehdashti F, Laforest R, Gao F, et al. Assessment of progesterone receptors in breast carcinoma by PET with 21-18F-fluoro-16alpha,17alpha-[(R)-(1'-alpha-furylmethylidene)dioxy]-19-norpregn-4-ene-3,20-dione. *J Nucl Med*. 2012;53:363-370.
50. Fowler AM, Clark AS, Katzenellenbogen JA, Linden HM, Dehdashti F. Imaging diagnostic and therapeutic targets: steroid receptors in breast cancer. *J Nucl Med*. 2016;57 Suppl 1:75s-80s.